Physician profile
John Reyes
NPI 1518142371
$2,839.69
in general payments reported to CMS, 2019-2025
23 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $217 · 2023: $639 · 2024: $584 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327 · Travel and Lodging: $140 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.21 |
| Travel and Lodging | $140.40 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $809.12 | 2022-2025 | |
| Medtronic, INC. | $382.61 | 2025 | Intellis Adaptivestim |
| Abbott Laboratories | $245.45 | 2022-2025 | 2nd Gen Centrimag Primary Console, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Lilly USA, LLC | $191.61 | 2022-2024 | Verzenio, Emgality, Reyvow |
| Biotronik Nro, INC. | $148.90 | 2025 | Prospera |
| Taiho Oncology, INC. | $124.99 | 2025 | |
| Seagen INC. | $124.40 | 2021 | |
| Merz Pharmaceuticals, LLC | $113.77 | 2024-2025 | Xeomin |
| Collegium Pharmaceutical, INC. | $112.81 | 2023-2025 | Belbuca |
| Pacira Pharmaceuticals Incorporated | $84.98 | 2023 | Iovera, Zilretta, Exparel |
| Idorsia Pharmaceuticals US INC | $77.04 | 2022-2024 | Quviviq |
| Lundbeck LLC | $74.45 | 2022-2024 | Vyepti |
| Pfizer INC. | $72.69 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $46.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.95 | 2024-2025 | Relistor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.27 | 2025 | Symbravo |
| Convatec INC. | $26.39 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $25.36 | 2025 | |
| Valinor Pharma, LLC | $24.76 | 2025 | Movantik |
| Clarus Therapeutics INC. | $22.55 | 2021 | |
| Cordis US Corp. | $21.71 | 2023 | Mynxgrip |
| Ibsa Pharma INC. | $16.99 | 2023 | Tirosint, Licart |
| Scilex Pharmaceuticals INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.